
Verve Therapeutics (VERV) Stock Forecast & Price Target
Verve Therapeutics (VERV) Analyst Ratings
Bulls say
Verve Therapeutics, Inc. is positioned to revolutionize the treatment of cardiovascular disease through its novel gene-editing medicines, reflecting a paradigm shift from chronic to single-course therapies that promise enhanced patient adherence and lower healthcare costs. The company holds a strong balance sheet with $540 million in cash, providing a financial runway into mid-2027, which supports its ongoing research and development efforts in promising pipelines such as PCSK9, ANGPTL3, and LPA. Additionally, the recent licensing agreement with BEAM, providing access to advanced base editing technology, exemplifies the growing pharmaceutical interest in gene editing and positions Verve favorably within the competitive landscape.
Bears say
Verve Therapeutics Inc reported a net loss of $0.58 per share in its 4Q24 earnings, with a projected full-year 2025 net loss of $2.38 per share, indicating ongoing financial challenges and a non-revenue generating status. The company's early-stage programs and the lack of imminent catalysts raise concerns about its ability to advance candidates through clinical assessments, alongside significant regulatory hurdles associated with gene-editing technologies for cardiovascular disease. Additionally, investors face speculative risks related to stock price volatility and potential dilution, further complicating the outlook for Verve Therapeutics's stock.
This aggregate rating is based on analysts' research of Verve Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Verve Therapeutics (VERV) Analyst Forecast & Price Prediction
Start investing in Verve Therapeutics (VERV)
Order type
Buy in
Order amount
Est. shares
0 shares